Evelo Biosciences (EVLO) Short Interest Ratio & Short Volume

Short interest is the volume of Evelo Biosciences shares that have been sold short but have not yet been closed out or covered. As of November 30th, investors have sold 197,000 shares of EVLO short. 2.11% of Evelo Biosciences' shares are currently sold short. Learn More on Evelo Biosciences' current short interest.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Evelo Biosciences: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.11% of Evelo Biosciences' floating shares are currently sold short.

Evelo Biosciences saw a decrease in short interest in the month of November. As of November 30th, there was short interest totaling 197,000 shares, a decrease of 54.2% from the previous total of 430,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Evelo Biosciences currently has issued a total of 18,980,000 shares. Some of Evelo Biosciences' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Evelo Biosciences currently has a public float of 9,340,000 shares.

2.11% of Evelo Biosciences' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Evelo Biosciences: Neptune Wellness Solutions Inc (0.54%), SciSparc Ltd. (24.15%), China SXT Pharmaceuticals, Inc. (4.78%), Biodexa Pharmaceuticals Plc (5.18%), Baudax Bio, Inc. (1.11%), Aditxt, Inc. (0.99%), Allarity Therapeutics, Inc. (9.18%), 180 Life Sciences Corp. (8.36%), PainReform Ltd. (1.21%), Aptevo Therapeutics Inc. (5.13%),

As of the most recent reporting period, the following stocks had the largest short interest positions: RTX Co. ($6.17 billion), Canadian Natural Resources Limited ($3.99 billion), T-Mobile US, Inc. ($3.78 billion), Charter Communications, Inc. ($3.37 billion), Coinbase Global, Inc. ($2.89 billion), Suncor Energy Inc. ($2.83 billion), Occidental Petroleum Co. ($2.64 billion), Tractor Supply ($2.31 billion), Royal Caribbean Cruises Ltd. ($1.73 billion), and Rivian Automotive, Inc. ($1.71 billion). View all of the most shorted stocks.

Short selling EVLO is an investing strategy that aims to generate trading profit from Evelo Biosciences as its price is falling. EVLO shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Evelo Biosciences occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of EVLO, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EVLO, twice per month. The most recent reporting period available is November, 30 2023.